CardiacPBPK

Prediction of drug effect is valuable in terms of both safety and efficacy. Modern model-based approaches can be useful in drug concentration-effect establishment, preceded by the estimation of active concentrations of drugs. With specifically cardiac safety and efficacy assessment in mind, we developed a mechanistic physiologically based pharmacokinetic (PBPK) model of the heart useful in assessment of the cardiac active drug fraction surrogate responsible for the clinically observed drug-related electrophysiological response in humans. The PBPK models were developed for a parent compound and its metabolite and include inter-subject variability. The models were written in R v.3.4.0. The detailed description of the models and the R code were published in Tylutki Z., Mendyk A., Polak S. J Pharm Sci, 2018, 107(4):1167-1177.